{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-11768"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-11768","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"The Role of L-fucose in Dendritic Cell Antigen Presentation and Polarization","abstract":"Since the FDA approval of IL-2 in cancer treatment in the 1980s, immunotherapy has emerged as the standard of care for several tumor types (e.g., melanoma, lung, bladder, colorectal). However, approximately 70 percent of cancer patients, independent of prior treatment or staging, administered immunotherapy will not achieve complete responses and will exhibit disease progression. Several factors have been identified to contribute to treatment failure, including the accumulation of intratumoral immunosuppressive cell populations, insufficient tumor-infiltrating anti-tumor immune populations, or the occurrence of immunoediting on tumor cells. Current strategies to circumvent immunosuppression either lack durable response to new immunosuppressive mechanisms the tumor develops or generate off-target toxicity towards healthy tissue. Therefore, there remains a need for innovative treatment options that can enhance the anti-tumor immune response safely while providing a durable response. Previously, our group discovered that oral administration of L-fucose decreases tumor growth in melanoma. Further evaluation of this phenomenon reveals that L-fucose-mediated tumor suppression depends on the immune system’s presence, specifically CD4+ T cells. Since CD4+ T cells are crucial for recruiting and activating other intratumoral immune subsets and forming immunological memory, treatment modalities that increase their abundance are expected to promote more robust and durable anti-tumor immune responses. Interestingly, further analysis of the differences in the tumor immune microenvironment of both breast and melanoma tumors reveals that this decrease in tumor volume is associated with an increase in intratumoral immune cells, including subpopulations of dendritic cells, particularly conventional type 1 and monocyte-derived dendritic cells. The intratumoral accumulation of these dendritic cell subtypes and CD4+ T cells suggests a vital role of dendritic cells in facilitating L-fucose-mediated tumor suppression. Additional studies revealed that L-fucose-treated dendritic cells exhibit an enhanced ability to activate T cells. This increase in T cell activation correlates with L-fucose-induced changes in the transcription of critical immunostimulatory and immunomodulatory cytokines in dendritic cells. Furthermore, L-fucose-treated dendritic cells exhibit increased rates of antigen uptake, processing, and presentation, resulting in greater stimulation of T cells. Together, these data represent the first study, to our knowledge, that suggests L-fucose as a novel adjuvant to enhance the functionality of dendritic cells. As we have shown, L-fucose promotes the polarization of dendritic cell subsets that have previously been used in dendritic cell vaccines (conventional type 1 and monocyte-derived dendritic cells), suggesting that L-fucose has the potential to enhance dendritic cell vaccine efficacy by increasing antigen uptake in dendritic cells to promote more efficient and effective activation of T cells.","abstract_html":"Since the FDA approval of IL-2 in cancer treatment in the 1980s, immunotherapy has emerged as the standard of care for several tumor types (e.g., melanoma, lung, bladder, colorectal). However, approximately 70 percent of cancer patients, independent of prior treatment or staging, administered immunotherapy will not achieve complete responses and will exhibit disease progression. Several factors have been identified to contribute to treatment failure, including the accumulation of intratumoral immunosuppressive cell populations, insufficient tumor-infiltrating anti-tumor immune populations, or the occurrence of immunoediting on tumor cells. Current strategies to circumvent immunosuppression either lack durable response to new immunosuppressive mechanisms the tumor develops or generate off-target toxicity towards healthy tissue. Therefore, there remains a need for innovative treatment options that can enhance the anti-tumor immune response safely while providing a durable response. Previously, our group discovered that oral administration of L-fucose decreases tumor growth in melanoma. Further evaluation of this phenomenon reveals that L-fucose-mediated tumor suppression depends on the immune system’s presence, specifically CD4+ T cells. Since CD4+ T cells are crucial for recruiting and activating other intratumoral immune subsets and forming immunological memory, treatment modalities that increase their abundance are expected to promote more robust and durable anti-tumor immune responses. Interestingly, further analysis of the differences in the tumor immune microenvironment of both breast and melanoma tumors reveals that this decrease in tumor volume is associated with an increase in intratumoral immune cells, including subpopulations of dendritic cells, particularly conventional type 1 and monocyte-derived dendritic cells. The intratumoral accumulation of these dendritic cell subtypes and CD4+ T cells suggests a vital role of dendritic cells in facilitating L-fucose-mediated tumor suppression. Additional studies revealed that L-fucose-treated dendritic cells exhibit an enhanced ability to activate T cells. This increase in T cell activation correlates with L-fucose-induced changes in the transcription of critical immunostimulatory and immunomodulatory cytokines in dendritic cells. Furthermore, L-fucose-treated dendritic cells exhibit increased rates of antigen uptake, processing, and presentation, resulting in greater stimulation of T cells. Together, these data represent the first study, to our knowledge, that suggests L-fucose as a novel adjuvant to enhance the functionality of dendritic cells. As we have shown, L-fucose promotes the polarization of dendritic cell subsets that have previously been used in dendritic cell vaccines (conventional type 1 and monocyte-derived dendritic cells), suggesting that L-fucose has the potential to enhance dendritic cell vaccine efficacy by increasing antigen uptake in dendritic cells to promote more efficient and effective activation of T cells.","abstract_has_math":false,"creators":["Burton, Chase J."],"institution":"University of South Florida","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Biology (Cell Biology, Microbiology, Molecular Biology)","degree_department":null,"school":null,"contributors":["Eric Lau, Ph.D.","Amer Beg, Ph.D.","Katherine MacNamara, Ph.D.","Eynav Klechevsky, Ph.D.","Paulo Rodriguez, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-06-27T07:00:00Z","date_published":"2024-06-27T07:00:00Z","updated_at":"2026-11-19T08:50:23Z","subjects":["Antigen-presenting cells","Cancer Immunology","Glycosylation","Immunotherapy","Immunology and Infectious Disease"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/10481","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/10481","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-11768","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Eric Lau, Ph.D.","Amer Beg, Ph.D.","Katherine MacNamara, Ph.D.","Eynav Klechevsky, Ph.D.","Paulo Rodriguez, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Burton, Chase J."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-06-27T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biology (Cell Biology, Microbiology, Molecular Biology)"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Antigen-presenting cells","Cancer Immunology","Glycosylation","Immunotherapy","Immunology and Infectious Disease"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/10481"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Since the FDA approval of IL-2 in cancer treatment in the 1980s, immunotherapy has emerged as the standard of care for several tumor types (e.g., melanoma, lung, bladder, colorectal). However, approximately 70 percent of cancer patients, independent of prior treatment or staging, administered immunotherapy will not achieve complete responses and will exhibit disease progression. Several factors have been identified to contribute to treatment failure, including the accumulation of intratumoral immunosuppressive cell populations, insufficient tumor-infiltrating anti-tumor immune populations, or the occurrence of immunoediting on tumor cells. Current strategies to circumvent immunosuppression either lack durable response to new immunosuppressive mechanisms the tumor develops or generate off-target toxicity towards healthy tissue. Therefore, there remains a need for innovative treatment options that can enhance the anti-tumor immune response safely while providing a durable response. Previously, our group discovered that oral administration of L-fucose decreases tumor growth in melanoma. Further evaluation of this phenomenon reveals that L-fucose-mediated tumor suppression depends on the immune system’s presence, specifically CD4+ T cells. Since CD4+ T cells are crucial for recruiting and activating other intratumoral immune subsets and forming immunological memory, treatment modalities that increase their abundance are expected to promote more robust and durable anti-tumor immune responses. Interestingly, further analysis of the differences in the tumor immune microenvironment of both breast and melanoma tumors reveals that this decrease in tumor volume is associated with an increase in intratumoral immune cells, including subpopulations of dendritic cells, particularly conventional type 1 and monocyte-derived dendritic cells. The intratumoral accumulation of these dendritic cell subtypes and CD4+ T cells suggests a vital role of dendritic cells in facilitating L-fucose-mediated tumor suppression. Additional studies revealed that L-fucose-treated dendritic cells exhibit an enhanced ability to activate T cells. This increase in T cell activation correlates with L-fucose-induced changes in the transcription of critical immunostimulatory and immunomodulatory cytokines in dendritic cells. Furthermore, L-fucose-treated dendritic cells exhibit increased rates of antigen uptake, processing, and presentation, resulting in greater stimulation of T cells. Together, these data represent the first study, to our knowledge, that suggests L-fucose as a novel adjuvant to enhance the functionality of dendritic cells. As we have shown, L-fucose promotes the polarization of dendritic cell subsets that have previously been used in dendritic cell vaccines (conventional type 1 and monocyte-derived dendritic cells), suggesting that L-fucose has the potential to enhance dendritic cell vaccine efficacy by increasing antigen uptake in dendritic cells to promote more efficient and effective activation of T cells."]},{"key":"dc:title","label":"Title","values":["The Role of L-fucose in Dendritic Cell Antigen Presentation and Polarization"]}]}],"canonical_facts":{"dc:contributor":["Eric Lau, Ph.D.","Amer Beg, Ph.D.","Katherine MacNamara, Ph.D.","Eynav Klechevsky, Ph.D.","Paulo Rodriguez, Ph.D."],"dc:creator":["Burton, Chase J."],"dc:date":["2024-06-27T07:00:00Z"],"dc:description":["Since the FDA approval of IL-2 in cancer treatment in the 1980s, immunotherapy has emerged as the standard of care for several tumor types (e.g., melanoma, lung, bladder, colorectal). However, approximately 70 percent of cancer patients, independent of prior treatment or staging, administered immunotherapy will not achieve complete responses and will exhibit disease progression. Several factors have been identified to contribute to treatment failure, including the accumulation of intratumoral immunosuppressive cell populations, insufficient tumor-infiltrating anti-tumor immune populations, or the occurrence of immunoediting on tumor cells. Current strategies to circumvent immunosuppression either lack durable response to new immunosuppressive mechanisms the tumor develops or generate off-target toxicity towards healthy tissue. Therefore, there remains a need for innovative treatment options that can enhance the anti-tumor immune response safely while providing a durable response. Previously, our group discovered that oral administration of L-fucose decreases tumor growth in melanoma. Further evaluation of this phenomenon reveals that L-fucose-mediated tumor suppression depends on the immune system’s presence, specifically CD4+ T cells. Since CD4+ T cells are crucial for recruiting and activating other intratumoral immune subsets and forming immunological memory, treatment modalities that increase their abundance are expected to promote more robust and durable anti-tumor immune responses. Interestingly, further analysis of the differences in the tumor immune microenvironment of both breast and melanoma tumors reveals that this decrease in tumor volume is associated with an increase in intratumoral immune cells, including subpopulations of dendritic cells, particularly conventional type 1 and monocyte-derived dendritic cells. The intratumoral accumulation of these dendritic cell subtypes and CD4+ T cells suggests a vital role of dendritic cells in facilitating L-fucose-mediated tumor suppression. Additional studies revealed that L-fucose-treated dendritic cells exhibit an enhanced ability to activate T cells. This increase in T cell activation correlates with L-fucose-induced changes in the transcription of critical immunostimulatory and immunomodulatory cytokines in dendritic cells. Furthermore, L-fucose-treated dendritic cells exhibit increased rates of antigen uptake, processing, and presentation, resulting in greater stimulation of T cells. Together, these data represent the first study, to our knowledge, that suggests L-fucose as a novel adjuvant to enhance the functionality of dendritic cells. As we have shown, L-fucose promotes the polarization of dendritic cell subsets that have previously been used in dendritic cell vaccines (conventional type 1 and monocyte-derived dendritic cells), suggesting that L-fucose has the potential to enhance dendritic cell vaccine efficacy by increasing antigen uptake in dendritic cells to promote more efficient and effective activation of T cells."],"dc:identifier":["https://digitalcommons.usf.edu/etd/10481"],"dc:subject":["Antigen-presenting cells","Cancer Immunology","Glycosylation","Immunotherapy","Immunology and Infectious Disease"],"dc:title":["The Role of L-fucose in Dendritic Cell Antigen Presentation and Polarization"],"thesis:degree_discipline":["Biology (Cell Biology, Microbiology, Molecular Biology)"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:50:23Z"}